Aurora Cannabis Inc.
ACB Healthcare Drug Manufacturers Specialty & Generic
Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.
Follow ACB
Aurora Cannabis Inc. (ACB) Piotroski F-score
Aurora Cannabis Inc.'s Piotroski F-score for fiscal 2026 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 4 | 0.00 |
| FY2023 | 4 | 0.00 |
| FY2022 | 4 | (1.00) |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | 1.00 |
| FY2019 | 3 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (16.82%) | 0.26% | Fail | 0 |
| Positive operating cash flow | (9.78m) | 11.50m | Fail | 0 |
| Rising return on assets | (16.82%) | 0.26% | Fail | 0 |
| Cash flow above net income | 78.35m | 9.87m | Pass | 1 |
| Falling long-term leverage | 0.03 | 0.09 | Pass | 1 |
| Rising current ratio | 5.94 | 4.31 | Pass | 1 |
| No new shares issued | 56,714,000 | 54,833,000 | Fail | 0 |
| Rising gross margin | 42.62% | 54.65% | Fail | 0 |
| Rising asset turnover | 0.44 | 0.40 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AKBA Akebia Therapeutics, Inc. compare | 7 |
| ANIK Anika Therapeutics Inc. compare | 6 |
| EBS Emergent Biosolutions Inc. compare | 6 |
| CGC Canopy Growth Corporation compare | 5 |
| SIGA Siga Technologies Inc. compare | 5 |
| TKNO Alpha Teknova, Inc. compare | 5 |
| ACB Aurora Cannabis Inc. | 4 |
| LFCR Lifecore Biomedical, Inc. compare | 3 |
| BIOA BioAge Labs, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover